<DOC>
	<DOCNO>NCT01264679</DOCNO>
	<brief_summary>To evaluate efficacy safety episodic treatment iron deficiency anemia ( IDA ) ferumoxytol .</brief_summary>
	<brief_title>A Trial Ferumoxytol Episodic Treatment Iron Deficiency Anemia Pediatric Subjects With Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Deficiency Diseases</mesh_term>
	<mesh_term>Ferrosoferric Oxide</mesh_term>
	<criteria>Key Inclusion Criteria include : 1 . Subjects complete participation study AMAGFERCKD251 AMAGFERCKD252 within past 4 week 2 . Female subject childbearing potential sexually active must effective method birth control agree remain birth control completion participation study 3 . Subject and/or legal guardian capable understand comply protocol requirement available duration study Key Exclusion Criteria include : 1 . Experienced serious adverse event ( SAE ) relate intravenous ( IV ) iron therapy study AMAGFERCKD251 AMAGFERCKD252 2 . Hemoglobin â‰¤7 g/dL</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Iron deficiency anemia , Feraheme , ferumoxytol , CKD , pediatric , dialysis-dependent , pediatric nondialysis-dependent</keyword>
</DOC>